SG11202002374RA - Compositions and methods for treating diffuse large b cell lymphoma - Google Patents
Compositions and methods for treating diffuse large b cell lymphomaInfo
- Publication number
- SG11202002374RA SG11202002374RA SG11202002374RA SG11202002374RA SG11202002374RA SG 11202002374R A SG11202002374R A SG 11202002374RA SG 11202002374R A SG11202002374R A SG 11202002374RA SG 11202002374R A SG11202002374R A SG 11202002374RA SG 11202002374R A SG11202002374R A SG 11202002374RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- cell lymphoma
- diffuse large
- treating diffuse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/055667 WO2019075366A1 (en) | 2017-10-13 | 2018-10-12 | Compositions and methods for treating diffuse large b cell lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002374RA true SG11202002374RA (en) | 2020-04-29 |
Family
ID=64110107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002374RA SG11202002374RA (en) | 2017-10-13 | 2018-10-12 | Compositions and methods for treating diffuse large b cell lymphoma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (en) |
| EP (1) | EP3694520A1 (en) |
| JP (2) | JP2020536923A (en) |
| KR (1) | KR20200068655A (en) |
| CN (1) | CN111212646A (en) |
| AU (1) | AU2018347457A1 (en) |
| BR (1) | BR112020007203A2 (en) |
| CA (1) | CA3075291A1 (en) |
| CL (1) | CL2020000973A1 (en) |
| EA (1) | EA202090565A1 (en) |
| IL (1) | IL273805A (en) |
| MX (1) | MX2020003395A (en) |
| SG (1) | SG11202002374RA (en) |
| TW (1) | TW201922283A (en) |
| WO (1) | WO2019075366A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
| US20230146593A1 (en) * | 2020-03-12 | 2023-05-11 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE120761T1 (en) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET. |
| PT1071752E (en) | 1998-04-21 | 2003-11-28 | Micromet Ag | SPECIFIC POLYMPEPTIDES FOR CD19XCD3 AND ITS USES |
| US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| CN109456410B (en) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | Cross-species specific CD 3-epsilon binding domains |
| DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| EP3302501B1 (en) | 2015-05-29 | 2021-09-22 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| EP3316888A1 (en) * | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/en unknown
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/en unknown
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en active Pending
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en active Pending
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/en active Pending
- 2018-10-12 EA EA202090565A patent/EA202090565A1/en unknown
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en active Pending
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en unknown
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/en unknown
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/en active Pending
- 2018-10-15 TW TW107136236A patent/TW201922283A/en unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/en unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024001071A (en) | 2024-01-09 |
| EP3694520A1 (en) | 2020-08-19 |
| IL273805A (en) | 2020-05-31 |
| CL2020000973A1 (en) | 2020-12-28 |
| TW201922283A (en) | 2019-06-16 |
| CA3075291A1 (en) | 2019-04-18 |
| KR20200068655A (en) | 2020-06-15 |
| WO2019075366A1 (en) | 2019-04-18 |
| CN111212646A (en) | 2020-05-29 |
| MX2020003395A (en) | 2020-08-03 |
| AU2018347457A1 (en) | 2020-04-09 |
| EA202090565A1 (en) | 2020-10-13 |
| BR112020007203A2 (en) | 2020-10-20 |
| US20200262919A1 (en) | 2020-08-20 |
| JP2020536923A (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295611B1 (en) | Method and device for processing tissues and cells | |
| IL282735A (en) | Compositions and methods for t cell engineering | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| SG11202005062SA (en) | Electrochemical methods, devices and compositions | |
| EP3701041A4 (en) | Methods and compositions for treating diseases associated with exhausted t cells | |
| EP3331582A4 (en) | Methods and compositions for treating cells for transplant | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| PT3377516T (en) | Methods and compositions for treating cancer | |
| IL269334A (en) | Improved t cell compositions and methods | |
| IL274837A (en) | Methods and compositions for treating cancers | |
| GB201611535D0 (en) | Methods and compositions for treating cancer with siglec-9 activity modulators | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| EP3384038A4 (en) | Methods and compositions for reprogramming cells | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL272246A (en) | Compositions and methods for treating galactosemia | |
| EP3122360A4 (en) | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma | |
| EP3271485A4 (en) | Methods for diagnosing and treating follicular lymphoma | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| EP3356598A4 (en) | Compositions and methods for treating filler in papermaking | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| EP3519058C0 (en) | Compositions and methods for treating hair |